ChemAnalyst Data Pvt Ltd

  Dolutegravir , a key antiretroviral drug used in the treatment of HIV, continues to hold significant importance in the global pharmaceutical landscape. As a core component of first-line HIV therapy, its market dynamics are closely monitored by healthcare providers, policymakers, and pharmaceutical stakeholders. In recent years, the price of Dolutegravir has undergone various shifts due to multiple influencing factors, including patent expirations, the rise of generic alternatives, global procurement strategies, and changes in supply and demand across regions. The pricing of Dolutegravir is not uniform; it varies depending on the region, the presence of generic competition, local manufacturing capabilities, and national healthcare policies. In developed markets, prices tend to remain higher due to brand loyalty, regulatory frameworks, and relatively limited competition. However, in emerging markets, particularly in low- and middle-income countries, the cost of Dolutegravir has dro...

  Dolutegravir   is an antiretroviral medication primarily used in the treatment of HIV/AIDS. As part of the class of drugs known as integrase inhibitors, Dolutegravir works by blocking the action of an enzyme called integrase, which the HIV virus uses to replicate. Since its approval by the U.S. Food and Drug Administration (FDA) in 2013, Dolutegravir has become a crucial component in many HIV treatment regimens. However, one of the most significant concerns around the world, especially in low-income and middle-income countries, has been the pricing of Dolutegravir. Pricing influences access to this essential medication, and efforts are ongoing to make it more affordable for those who need it most. The cost of Dolutegravir varies widely depending on geographic location, patent laws, and whether the drug is branded or generic. In high-income countries such as the United States, Dolutegravir is often sold under the brand name Tivicay, manufactured by ViiV Healthcare. The brand-...